1
|
Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
2
|
Yoh K, Kenmotsu H, Yamamoto N, Misumi T, Takahashi T, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
3
|
Miyaguni Y, Agarie A, Sugio K, Tsuji K, Kobayashi K. Caste development and sex ratio of the Ryukyu drywood termite Neotermes sugioi and its potential mechanisms. Sci Rep 2021; 11:15037. [PMID: 34294796 PMCID: PMC8298410 DOI: 10.1038/s41598-021-94505-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 07/05/2021] [Indexed: 02/06/2023] Open
Abstract
Sex allocation is one of the most studied traits in evolutionary biology because its theoretical predictions match the empirical data. Here, using the Ryukyu dry-wood termite Neotermes sugioi, we investigated several factors that could bias the sex allocation in three populations (Okinawa, Ishigaki/Iriomote, and Yonaguni). Our survey showed that there were more queen-only colonies than king-only colonies in these populations, suggesting a longer lifespan of the queens than that of the kings. In this condition, sex-asymmetric reproductive value (SRV) theory predicts female bias, because even after the short-lived kings die, the long-lived queens can continue reproduction with their sons. However, sex allocation in this species seemed to be biased toward males. Furthermore, we examined the possibility of intrasexual competition among siblings (ICS). If ICS is the cause of the bias, the allocation is expected to change depending on the total investment in sexual offspring. However, the biomass of both male and female alates increased linearly with the increase in the total biomass of the alates in these populations. Thus, neither the SRV nor the ICS theory could explain the male-biased sex ratio of N. sugioi. On the basis of these results, we discuss the remaining possibilities in this species.
Collapse
Affiliation(s)
- Y Miyaguni
- Global Education Institute, University of the Ryukyus, Okinawa, 903-0213, Japan
| | - A Agarie
- Department of Environmental Science and Conservation Biology, United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima, 890-8580, Japan
| | - K Sugio
- Graduate School of Education, University of the Ryukyus, Nishihara, Okinawa, 903-0213, Japan
| | - K Tsuji
- Entomological Laboratory, Faculty of Agriculture, University of the Ryukyus, Okinawa, 903-0213, Japan
| | - K Kobayashi
- Field Science Education and Research Center, Hokkaido Forest Research Station, Kyoto University, 553 Tawa, Shibecha-cho, Kawakami-gun, Hokkaido, 088-2339, Japan.
| |
Collapse
|
4
|
Hotta K, Saeki S, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Gemba K, Shiojiri M, Kato Y, Ninomiya T, Kubo T, Kishimoto J, Shioyama Y, Katsui K, Sasaki J, Kiura K, Sugio K. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study. ESMO Open 2021; 6:100191. [PMID: 34153652 PMCID: PMC8233144 DOI: 10.1016/j.esmoop.2021.100191] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 05/13/2021] [Accepted: 05/26/2021] [Indexed: 12/02/2022] Open
Abstract
Background The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung cancer (NSCLC). Therefore, a phase II trial was conducted to evaluate the efficacy and safety of gefitinib induction followed by CRT in this disease setting. Patients and methods Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib monotherapy (250 mg/day) for 8 weeks. Subsequently, patients without disease progression during induction therapy were administered cisplatin and docetaxel (40 mg/m2 each) on days 1, 8, 29, and 36 with concurrent radiotherapy at a total dose of 60 Gy. The primary endpoint was the 2-year overall survival (OS) rate, which was hypothesized to reach 85%, with a threshold of the lower limit of 60%. Results Twenty patients (median age: 66 years; male/female: 9/11; histology: 20 adenocarcinoma; stage IIIA/IIIB: 9/11; and exon 19/21: 10/10) were enrolled. The 2-year OS rate was 90% (90% confidence interval: 71.4% to 96.8%), indicating that this trial met the primary objective. The overall response rate and 1- and 2-year progression-free survival rates were 85.0%, 58.1%, and 36.9%, respectively. Grade ≥3 adverse events (>10%) included hepatic toxicity during the induction phase and neutropenia and febrile neutropenia in the CRT phase. Radiation pneumonitis grade ≥3 or treatment-related death did not occur. Conclusions This is the first prospective study to demonstrate the favorable efficacy and safety of EGFR-TKI induction followed by standard CRT in EGFR-mutant, stage III NSCLC. Further confirmatory studies are needed. This is the first prospective study evaluating gefitinib induction followed by CRT in EGFR-mutated, locally advanced NSCLC. The 2-year OS rate was 90% (90% confidence interval: 71.4% to 96.8%), indicating that this trial met the primary objective. The objective response rate throughout the treatment protocol was 85.0% (17 of 20). The safety findings were consistent with the known safety profiles of all agents administered. Our results might raise a critical point that needs to be evaluated in further studies to improve the cure rate.
Collapse
Affiliation(s)
- K Hotta
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
| | - S Saeki
- Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan
| | - M Yamaguchi
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Kyushu, Japan
| | - D Harada
- Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Shikoku, Japan
| | - A Bessho
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan
| | - K Tanaka
- Department of Respiratory Medicine, Kyushu University Hospital, Kyushu, Japan
| | - K Inoue
- Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - K Gemba
- Department of Respiratory Medicine, Chugoku Central Hospital, Chugoku, Japan
| | - M Shiojiri
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Ehime, Japan
| | - Y Kato
- Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan; Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
| | - T Ninomiya
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Shikoku, Japan
| | - T Kubo
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
| | - J Kishimoto
- Center for Clinical and Translational Research, Kyushu University Hospital, Kyushu, Japan
| | - Y Shioyama
- Clinical Radiology, Radiology Informatics and Network, Graduate School of Medical Sciences, Kyushu University, Kyushu, Japan
| | - K Katsui
- Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - J Sasaki
- Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Kitasato, Japan
| | - K Kiura
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
| | - K Sugio
- Department of Thoracic and Breast Surgery, Oita University, Oita, Japan
| |
Collapse
|
5
|
Mouri A, Tanaka K, Asahina H, Kishimoto J, Okada M, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oizumi S, Okamoto I. FP14.02 A Phase II Study of Osimertinib versus Combination of Osimertinib and Chemotherapy for EGFR and T790M-Mutation Positive NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Saeki S, Hotta K, Yamaguchi M, Harada D, Bessho A, Tanaka K, Inoue K, Gemba K, Inoue K, Ichihara E, Kishimoto J, Sasaki T, Shioyama Y, Katsui K, Sasaki J, Kiura K, Sugio K. Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations: The LOGIK0902/OLCSG0905 intergroup phase II study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz436] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
|
7
|
Tsuboi M, Kenmotsu H, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Yamamoto N. JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Maruyama R, Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Nakagaki N, Kishimoto J, Ichinose Y, Sugio K. P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Osoegawa A, Hashimoto T, Takumi Y, Kobayashi R, Miyawaki M, Takeuchi H, Okamoto T, Sugio K. P3.02-039 Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Kenmotsu H, Iwama E, Goto Y, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. P1.03-004 Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tagawa T, Emi Y, Maehara Y. A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T > 5cm), II, IIIA non-small cell lung cancer comparing S-1 versus S-1 with cisplatin. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. Diabetes Obes Metab 2016; 18:702-6. [PMID: 26639943 PMCID: PMC5066655 DOI: 10.1111/dom.12611] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Revised: 11/05/2015] [Accepted: 11/30/2015] [Indexed: 12/30/2022]
Abstract
This randomized, double-blind, placebo-controlled, crossover study was the first to determine the effects of luseogliflozin in combination with a low-carbohydrate diet (LCD) on 24-h glucose variability, assessed by continuous glucose monitoring (CGM). A total of 18 Japanese patients with type 2 diabetes were randomized into two groups, in which patients first received luseogliflozin 2.5 mg once daily then placebo for 8 days each, or vice versa. Patients took luseogliflozin or placebo with a normal-carbohydrate diet (NCD) on day 7 and with the LCD on day 8. CGM was performed on both days. Luseogliflozin significantly reduced glucose exposure in terms of the area under the curve over the course of 24 h when administered with the NCD (difference vs placebo: -555.6 mg/dl·h [1 mg/dl = 0.0556 mmol/l]; p < 0.001) or with the LCD (-660.7 mg/dl·h; p < 0.001). No hypoglycaemia was observed over 24 h with either diet. Although glucose levels were lower with the LCD than with the NCD in the placebo treatment period, luseogliflozin with the LCD improved glycaemic control throughout the day to nearly the same extent as luseogliflozin with the NCD, without inducing hypoglycaemia.
Collapse
Affiliation(s)
- R. Nishimura
- Division of Diabetes, Metabolism and Endocrinology, Department of Internal MedicineJikei University School of MedicineTokyoJapan
| | - H. Omiya
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - K. Sugio
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - M. Ubukata
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | - S. Sakai
- Taisho Pharmaceutical Co., Ltd.TokyoJapan
| | | |
Collapse
|
13
|
Tsuda M, Kiyasu J, Sugio K, Hidaka D, Ikeda M, Fujioka E, Souri M, Osaki T, Yufu Y, Ichinose A. Spontaneous splenic rupture accompanied by hepatic arterial dissection in a patient with autoimmune haemorrhaphilia due to anti-factor XIII antibodies. Haemophilia 2016; 22:e314-7. [DOI: 10.1111/hae.12940] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/16/2016] [Indexed: 12/22/2022]
Affiliation(s)
- M. Tsuda
- Department of Hematology; Iizuka Hospital; Iizuka Japan
| | - J. Kiyasu
- Department of Hematology; Iizuka Hospital; Iizuka Japan
| | - K. Sugio
- Central Laboratory; Iizuka Hospital; Iizuka Japan
| | - D. Hidaka
- Central Laboratory; Iizuka Hospital; Iizuka Japan
| | - M. Ikeda
- Department of Hematology; Iizuka Hospital; Iizuka Japan
| | - E. Fujioka
- Department of Hematology; Iizuka Hospital; Iizuka Japan
| | - M. Souri
- Department of Molecular Patho-Biochemistry and Patho-Biology; Yamagata University School of Medicine; Yamagata Japan
- The Japanese Collaborative Research Group (JCRG) on Autoimmune hemorrha-philia due to anti-factor XIII antibodies (AH13); Yamagata Japan
| | - T. Osaki
- Department of Molecular Patho-Biochemistry and Patho-Biology; Yamagata University School of Medicine; Yamagata Japan
- The Japanese Collaborative Research Group (JCRG) on Autoimmune hemorrha-philia due to anti-factor XIII antibodies (AH13); Yamagata Japan
| | - Y. Yufu
- Department of Hematology; Iizuka Hospital; Iizuka Japan
| | - A. Ichinose
- Department of Molecular Patho-Biochemistry and Patho-Biology; Yamagata University School of Medicine; Yamagata Japan
- The Japanese Collaborative Research Group (JCRG) on Autoimmune hemorrha-philia due to anti-factor XIII antibodies (AH13); Yamagata Japan
| |
Collapse
|
14
|
Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, Ubukata M, Sakai S, Samukawa Y. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab 2015; 17:800-4. [PMID: 25930989 PMCID: PMC5032984 DOI: 10.1111/dom.12481] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Revised: 04/14/2015] [Accepted: 04/28/2015] [Indexed: 11/27/2022]
Abstract
The aim of the present study was to determine the effects of luseogliflozin on 24-h glucose levels, assessed by continuous glucose monitoring, and on pharmacodynamic variables measured throughout the day. In this double-blind, placebo-controlled, crossover study, 37 patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized into two groups. Patients in each group first received luseogliflozin then placebo for 7 days each, or vice versa. After 7 days of treatment, the mean 24-h glucose level was significantly lower with luseogliflozin than with placebo [mean (95% confidence interval) 145.9 (134.4-157.5) mg/dl vs 168.5 (156.9-180.0) mg/dl; p < 0.001]. The proportion of time spent with glucose levels ≥70 to ≤180 mg/dl was significantly greater with luseogliflozin than with placebo [median (interquartile range) 83.2 (67.7-96.5)% vs 71.9 (46.9-83.3)%; p < 0.001] without inducing hypoglycaemia. The decrease in glucose levels was accompanied by reductions in serum insulin levels throughout the day.
Collapse
Affiliation(s)
- R Nishimura
- Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - T Osonoi
- Naka Kinen Clinic, Ibaraki, Japan
| | | | | | - K Sugio
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - H Omiya
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - M Ubukata
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - S Sakai
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| | - Y Samukawa
- Taisho Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
15
|
Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku N. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Ann Oncol 2013; 24:1653-9. [PMID: 23413279 DOI: 10.1093/annonc/mdt014] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Tivantinib (formerly ARQ 197) is a selective inhibitor of c-Met mainly metabolized by CYP2C19. CYP2C19 is known for genetic polymorphisms, and ~20% of Asians are poor metabolizers (PMs), while others are extensive metabolizers (EMs). In this study, we examined the safety, pharmacokinetics (PK), and preliminary efficacy of tivantinib as a single agent to determine recommended phase II doses (RPIIDs). PATIENTS AND METHODS Forty-seven patients (EMs, 33; PMs, 14) with solid tumors were orally treated with tivantinib, from 70 to 360 mg bid in a 3 + 3 dose-escalation scheme. EMs and PMs were separately enrolled at the doses >120 mg bid. RESULTS Tivantinib was well tolerated up to 360 mg bid for EMs and 240 mg bid for PMs. Neutropenia, leukopenia, anemia, fatigue, and anorexia were the frequent adverse events related to tivantinib and were commonly observed in both EMs and PMs. PMs had 1.9-fold higher AUC(0-12) compared with EMs at 240 mg bid. Regardless of CYP2C19 phenotype, Gr.4 neutropenia occurred in patients with relatively high exposure to tivantinib. A confirmed partial response was achieved in two non-small-cell lung cancer (NSCLC) patients. CONCLUSION Two different settings of RPIIDs, 360 mg bid for EMs and 240 mg bid for PMs, were determined.
Collapse
Affiliation(s)
- N Yamamoto
- Division of Thoracic Oncology, Shizuoka Cancer Center, Naga-izumi, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Toyokawa G, Hamamoto R, Sugio K, Ichinose Y, Nakamura Y. Minichromosome Maintenance Protein 7 Plays Essential Roles in Cancer Cell Growth and is a Potential Therapeutic Target in Human Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32264-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
17
|
Tada H, Takeda K, Nakagawa K, Okamoto I, Mitsudomi T, Ichinose Y, Sugio K, Tsuboi M, Nakanishi Y. Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small-Cell Lung Cancer Haboring Activating EGFR Mutation (WJOG6410L). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)31981-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
18
|
Okada H, Murakami H, Yamanaka T, Seto T, Sugio K, Okamoto I, Sawa T, Hirashima T, Nakamura S, Fukuoka M, Nakanishi Y, Nakagawa K, Yamamoto N. Randomized Phase II Trial of Zoledronic Acid in Combination with Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (NSCLC) Patients with Bone Metastases: WJTOG3806. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32040-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
19
|
Fujisaka Y, Yamamoto N, Hirashima T, Takeda K, Sugio K, Satouchi M, Nakagawa K. Phase I Trials of a C-MET Inhibitor ARQ 197 in Combination with an EGFR Inhibitor Erlotinib in Advanced/Metastatic Non-Small Cell Lung Carcinoma (ARQ 197-003/005 Trial). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32293-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Toyokawa G, Ohba T, Sugio K, Morodomi Y, Takenaka T, Yamaguchi M, Hirai F, Taguchi K, Seto T, Ichinose Y. The Role of Mutations of EGFR, K-RAS, EML4-ALK, and B-RAF Genes in Resected Pathological Stage I Lung Adenocarcinoma. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33750-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
21
|
Sasaki T, Uehara S, Abe M, Shioyama Y, Nakamura K, Sugio K, Ichinose Y, Hirata H, Honda H. Treatment Efficacy Of Preoperative Chemoradiotherapy For Patients With Locally Advanced Non-small cell Lung Cancer. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.1861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
22
|
Nishina T, Hirashima T, Sugio K, Muro K, Akinaga S, Maeda H, Takahashi T, Naito T, Murakami H, Yasui H, Boku N, Yamamoto N. The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2516] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Ohba T, Sugio K, Kometani T, Yamaguchi M, Hamatake M, Nosaki K, Takeoka H, Kitajima H, Hirai F, Seto T, Ichinose Y. Mutations of EGFR, K-ras, and EML-4ALK genes in resected lung adenocarcinoma and their clinical significance. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Kogure Y, Ando M, Chiba Y, Yamamoto N, Asami K, Hirashima T, Sugio K, Ikeda N, Saka H, Nakagawa K. Impact of histology and smoking status on survival outcome of patients with advanced non-small cell lung cancer (NSCLC): West Japan Oncology Group (WJOG) study 3906L. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K. Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7562 Background: Carboplatin plus paclitaxel and carboplatin plus gemcitabine chemotherapy have shown a good response and an improved survival against advanced NSCLC. This phase II trial assessed the feasibility, safety and efficacy of a bi-weekly schedule for adjuvant chemotherapy. Methods: Patients with completely resected stage IB-IIIB NSCLC were randomized to either carboplatin (AUC3) plus paclitaxel (90mg/m2) (arm A) or carboplatin (AUC3) plus gemcitabine (1000 mg/m2) (arm B), q2w for 8 cycles within 8 weeks after surgery. The main inclusion criteria were no prior chemotherapy or radiotherapy, ECOG PS 0–1, an age of less than 80 years, and an adequate organ function. The primary endpoint was compliance, and secondary endpoints were the disease free survival (DFS) and toxicity. The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage. Results: Between 07/2005 and 06/2007, 76 patients were randomized and 75 were eligible (including 48 males, 27 females; median age 66 years) for intent-to-treat analysis (39 in arm A, 36 in arm B). The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1). The pathological stages were IB/IIA/IIB/IIIA/IIIB: 22/10/13/29/1. Twenty-one of 39 pts (54%) in arm A and 25 of 36 pts (69%) in arm B completed 8 cycles, and 59% in arm A and 81% in arm B completed ≥6 cycles. Grade 3/4 hematologic toxicities (%) in arms A/B were respectively; neutropenia 36/53, anemia 0/17, thrombocytopenia 3/0, nausea 3/3. No treatment related deaths were observed. Up to 12/2008, 11 of 39 pts in arm A and 13 of 36 pts in arm B had recurrent disease, but no significant difference was observed. Conclusions: This adjuvant bi- weekly scheduled chemotherapy in both arms resulted in a good compliance and feasible with acceptable levels of toxicity in completely resected NSCLC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Sugio
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - A. Nagashima
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - R. Nakanishi
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - A. Uchiyama
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - M. Inoue
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Osaki
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Yoshimatsu
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - M. Takenoyama
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - T. Hanagiri
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| | - K. Yasumoto
- University of Occupational & Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shin-Kokura Hospital, Kitakyushu, Japan; Kyushu Kousei Nenkin Hospital, Kitakyushu, Japan; Niigata Rosai Hospital, Joetsu, Japan; Iizuka Hospital, Iizuka, Japan; Fukuoka Wajiro Hospital, Fukuoka, Japan
| |
Collapse
|
26
|
Morita S, Hirashima T, Hagiwara K, Hida T, Sunaga N, Sugio K, Inoue A, Yamazaki K, Mitsudomi T, Nukiwa T. Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8101] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, Kakeji Y, Ichiki Y, Sugio K, Yasumoto K, Maehara Y. Acute lung injury following an esophagectomy for esophageal cancer, with special reference to the clinical factors and cytokine levels of peripheral blood and pleural drainage fluid. Dis Esophagus 2008; 21:30-6. [PMID: 18197936 DOI: 10.1111/j.1442-2050.2007.00725.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Acute lung injury (ALI) is one of most serious complications to occur after an esophagectomy for esophageal cancer. However, the pathogenesis of ALI is still unclear. The cytokine levels of pleural drainage fluid as well as peripheral blood were measured in 27 patients who had undergone an extended radical esophagectomy. Both the clinical factors and cytokine levels were compared between 11 patients with (group I) and 16 without ALI (group II). ALI occurred more frequently in patients who underwent colon interposition than in those who received a gastric tube reconstruction (86%vs 25%, P = 0.009). The operation time of group I was significantly longer than that of group II. A logistic regression analysis revealed colon interposition to be an independent factor associated with the ALI (P < 0.05). Postoperative anastomotic leakage and systemic inflammatory response syndrome (SIRS) occurred more frequently in group I than in group II (P < 0.01). Both the serum interleukin-6 (IL-6) and IL-8 levels of group I were significantly higher than those of group II. IL-1beta and tumor necrosis factor-alpha were undetectable in the peripheral blood, whereas they were detectable in the pleural effusion. The IL-1beta of pleural effusion was higher in group I than group II. In conclusion, greater surgical stress, such as a longer operative time, is thus considered to be associated with the first attack of ALI. The adverse events developing in the extra-thoracic site, such as necrosis and local infection around anastomosis may therefore be the second attack. Furthermore, ALI may cause not only SIRS but also other complications such as anastomotic leakage.
Collapse
Affiliation(s)
- M Morita
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Uramoto H, Sugio K, Oyama T, Iwata T, Onizuka T, Yasuda M, Sugaya M, Nozoe T, Takenoyama M, Hanagiri T, Yasumoto K. Secondary T790M mutation and novel G796A mutation in exon20 of EGFR gene in patients with non-small cell lung cancer who show resistance to gefitinib. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7703 Background: Somatically acquired mutations in the EGFR gene in non-small cell lung cancer are associated with a significant clinical response to a tyrosine kinase inhibitor (TKI). EGFR mutations occur predominantly in exon19 and/or exon21, namely, an in-frame deletion in exon19 or a missense mutation in exon21 (L858R), which have been found to be related to the sensitivity to TKI. However, most patients with such sensitive mutations in their tumor show progression during the TKI treatment. In such resistant tumors, a secondary threonine- to-methionine mutation at codon 790 (T790M) in exon20 has been reported to be related the resistance to either gefitinib or erlotinib. Methods: EGFR mutations in exons19–21 were examined by sequencing in 37 pretreatment tumors obtained from patients with NSCLC, who were treated by gefitinib. Of the 22 cases having sensitive EGFR mutations (19del or L858R), 15 showed CR/PR and 7 showed SD/PD. Of the 15 patients with CR/PR, 4 tumor samples (2 lung, 1 liver, and 1 pleural effusion) that became refractory to gefitinib, were obtained. In pretreatment tumor samples from 4 patients, an in-frame deletion of exon19 was observed in 3 tumors and a L858R mutation of exon21 was in 1 tumor. We next examined whether a secondary mutation occurred in a tumor with acquired resistance to gefitinib in 4 patients by the sequencing of exons 19–21, with informed consent. Results: Three of 4 tumor samples had a secondary T790M mutation, which was not detected in the pretreatment tumor samples. These 3 samples also had an in-frame deletion in exon19. There were no other novel secondary mutations in exons 19,20,21. In 7 cases showing resistance to gefitinib (SD/PD) in spite of the existence of sensitive mutations, 1 tumor demonstrated the co-existence of a missense mutation (G796A) in exon20. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to the cells carrying exon19 deletion. Conclusions: The T790M mutation is common in patients with acquired resistance to gefitinb. Our results suggest that screening tumor samples for a range of EGFR mutations may therefore improve our ability to identify the patients most likely to benefit from treatment with TKI. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Uramoto
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - K. Sugio
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - T. Oyama
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - T. Iwata
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - T. Onizuka
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - M. Yasuda
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - M. Sugaya
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - T. Nozoe
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - M. Takenoyama
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - T. Hanagiri
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| | - K. Yasumoto
- University of Occupational and Environmental Healt, Kitakyushu, Japan
| |
Collapse
|
29
|
Sugio K, Uramoto H, Oyama T, Onizuka T, Ichiki Y, Yasuda M, Sugaya M, Nozoe T, Takenoyama M, Hanagiri T, Yasumoto K. A prospective phase II study of gefitinib in non-small cell cancer patients with epidermal growth factor receptor gene (EGFR) mutations. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18081 Background: Somatically acquired mutations in the EGFR gene in non-small cell lung cancer are associated with a significant clinical response to gefitinib, a tyrosine kinase inhibitor that targets EGFR, especially in patients with adenocarcinoma, females, and/or never/light smokers. In our retrospective study, cases with EGFR mutations (exon19del or L858R) showed a high sensitivity to gefitinib, and the patients with sensitive EGFR mutations also tended to have a more favorable prognosis than those with wild-type after gefitinib treatment (Uramoto, et al. Lung Cancer 2006;51:71). In the present study, we prospectively assessed the efficacy of gefitinib and the survival benefit for patients with EGFR mutations. Methods: Patients with either recurrent disease after undergoing surgery or advanced disease (IIIB or IV) of NSCLC which demonstrated EGFR mutations were eligible for this study. EGFR mutations in exons 19–21 were examined by our previously described screening method (Sugio, et al. Br J Cancer 2006;94:896) and confirmed by direct sequencing after informed consent was obtained from all patients. The patients with EGFR mutations were enrolled in this study after obtaining informed consent a second time, and they were thereafter treated with gefitinib. Results: Between 2005 and 2006, 16 patients (10 males/6 females, all adenocarcinoma) who had EGFR mutations were enrolled onto this study. Six pts had a deletion in exon 19, 8 pts had a missense mutation in exon 21 (L858R), 1 pt had both an exon 19 del and L858R, and 1 pts had an exon19 del and missense mutation in exon 20 (G796A). The overall response rate was 50%, and the disease control rate was 88%. In patients with exon19 del and L858R, the response rates were 83% and 25%, respectively. A case with a deletion in exon19 and a missense mutation in exon20 (G796A) showed resistance to gefitinib. The median progression-free survival time was 8.8 months, and the median survival time was 15.4 months. No life-threatening toxicity was observed. Conclusions: EGFR mutations in exons 19 or 21 are therefore considered to a good predictor of the efficacy of gefitinib, and the treatment with gefitinib was also found to achieve a prolonged survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Sugio
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - H. Uramoto
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Oyama
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Onizuka
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Y. Ichiki
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Yasuda
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Sugaya
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Nozoe
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Takenoyama
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Hanagiri
- University of Occupational and Environmental Health, Kitakyushu, Japan
| | - K. Yasumoto
- University of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
30
|
Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otsuji Y, Kohno K. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26:4749-60. [PMID: 17297441 DOI: 10.1038/sj.onc.1210289] [Citation(s) in RCA: 106] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.
Collapse
Affiliation(s)
- T Igarashi
- Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Yoshino I, Ichinose Y, Nagashima A, Takeo S, Motohiro A, Yano T, Ishida T, Yamazaki K, Sugio K, Yasumoto K, Maehara Y. Clinical characterization of node-negative non-small cell lung cancer: Results of a prospective investigation. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7218 Background: 20 to 30% of clinical stage IA non-small cell lung cancer cases were revealed to be node-positive by pathologic examination of resected specimens. In this prospective study, the clinical features of a truly node-negative population were prospectively investigated to search for candidates of a lesser resection or of a stereotactic radiotherapy. Methods: The clinical data and radiographic features of high-resolution computed tomography (HR-CT) were registered before operation in 169 clinical stage IA lung cancer patients, who were scheduled to undergo a standard lobectomy and systemic mediastinal node dissection. The nodal metastasis was pathologically defined, while the clinical factors associated with the presence of the nodal metastasis were evaluated. Results: In 130 evaluable cases, 16 of 114 adenocarcinoma and 3 of 16 other NSCLC were node-positive. Among all parameters, positivity of the serum carcinoembryonic antigen (CEA) was the only factor significantly associated with nodal metastasis (p = 0.0074). When we focused on adenocarcinomas, the serum CEA, retraction sign and intratumoral air-space on HR-CT were suggested to be predictive factors for lymph node metastasis with hazard ratios of 12.44 (p = 0.0003), 6.53 (p = 0.0533) and 0.17 (0.0073), respectively. In combination with the radiologic features of HR-CT imaging, none of 18 CEA-negative/retraction-negative cases and 3 of 65 CEA-negative/air-space positive cases showed nodal metastasis, in which the incidence of nodal metastasis was significantly lower than the counterparts with respective p-values of 0.0015 and 0.037. The tumor size and the proportion of ground glass attenuation were not associated with the incidence of nodal metastasis. Conclusions: The serum CEA and HR-CT features thus allowed us to identify node-negative lung adenocarcinomas. In clinical stage IA adenocarcinoma cases, a standard operation should be considered when positive serum CEA and/or retraction sign on HRCT is noticed. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Yoshino
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - Y. Ichinose
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - A. Nagashima
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - S. Takeo
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - A. Motohiro
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - T. Yano
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - T. Ishida
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Yamazaki
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Sugio
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - K. Yasumoto
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| | - Y. Maehara
- Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; Kyushu Lung Cancer Surgery Cooperative Group, Fukuoka, Japan
| |
Collapse
|
32
|
Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, Ichiki Y, So T, Nakata S, Morita M, Yasumoto K. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94:896-903. [PMID: 16552419 PMCID: PMC3216424 DOI: 10.1038/sj.bjc.6603040] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Somatically acquired mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer are associated with significant clinical responses to gefitinib, a tyrosine kinase inhibitor that targets EGFR. We screened the EGFR in 469 resected tumours of patients with lung cancer, which included 322 adenocarcinomas, 102 squamous cell carcinomas, 27 large cell carcinomas, 13 small cell carcinomas, and five other cell types. PCR with a specific condition was performed to identify any deletion in exon 19, while mutant-allele-specific amplification was performed to identify a mutation in codon 858 of exon 21. EGFR mutations were found in 136 cases (42.2%) with adenocarcinoma, in one case with large cell carcinoma, and in one case with pleomorphic carcinoma. An in-frame deletion in exon 19 was found in 62 cases while an L858R mutation was found in 77 cases. In the 322 cases with adenocarcinoma, these mutations were more frequently found in women than in men (P=0.0004), in well differentiated tumours than in poorly differentiated tumours (P=0.0014), and in patients who were never smokers than in patients who were current/former smokers (P<0.0001). The mutation was more frequently observed in patients who smoked ⩽20 pack-year, and in patients who quit at least 20 years before the date of diagnosis for lung cancer. The K-ras mutations were more frequently found in smokers than in never smokers, and in high-dose smokers than in low-dose smokers. In conclusion, the mutations within the tyrosine kinase domain of EGFR were found to specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking.
Collapse
Affiliation(s)
- K Sugio
- Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu, 807-8555 Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
So T, Hanagiri T, Mizukami M, Ichiki Y, Sugaya M, Takenoyama M, Sugio K, Yasumoto K. PD-027 Abnormal HLA expression as an immune escape mechanism inlung cancer cell lines. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80360-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
34
|
Hanagiri T, Sugaya M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Takenoyama M, Sugio K, Yasumoto K. PD-012 Establishment of lung cancer cell lines and identification of tumor antigens recognized by CTL. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80344-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Mizukami M, Hanagiri T, Fukuyama T, So T, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Sugio K, Yasumoto K. O-022 Identification of antigens in lung cancer by using IgG derived from tumor-infiltrating B lymphocytes. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80154-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Sugio K, Uramoto H, Hanagiri T, Oyama T, Yoshimatsu T, Sugaya M, Ono K, Nakata S, Morita M, Yasumoto K. PD-158 Mutations in the EGFR gene as predictors of gefitinib-sensitivity specifically occur in lung adenocarcinoma patients with a relatively low exposure of tobacco smoking. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80491-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Sugio K, Uramoto H, Morita M, Oyama T, Hanagiri T, Yoshimatsu T, Sugaya M, Ono K, Yasumoto K. Mutations in the EGFR gene demonstrating a close association with gefitinib-sensitivity specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Sugio
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - H. Uramoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Morita
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Oyama
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Hanagiri
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - T. Yoshimatsu
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - M. Sugaya
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - K. Ono
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| | - K. Yasumoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan
| |
Collapse
|
38
|
Sugaya M, Sugio K, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Ono K, Uramoto H, Hanagiri T, Yasumoto K. Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7258] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Sugaya
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Sugio
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - A. Nagashima
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - R. Nakanishi
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - H. Sakata
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Nakanishi
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Ono
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - H. Uramoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - T. Hanagiri
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| | - K. Yasumoto
- Univ. of Occupational and Environmental Health, Kitakyushu, Japan; Kitakyushu Municipal Medcl Ctr, Kitakyushu, Japan; Shinkokura Hosp, Kitakyushu, Japan; Shinnittetsu Yahata Memorial Hosp, Kitakyushu, Japan; Iizuka Hosp, Iizuka, Japan
| |
Collapse
|
39
|
Gu C, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, Sugio K, Kohno K, Yasumoto K. Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence. Br J Cancer 2004; 90:436-42. [PMID: 14735190 PMCID: PMC2409559 DOI: 10.1038/sj.bjc.6601531] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2003] [Revised: 08/12/2003] [Accepted: 11/05/2003] [Indexed: 11/29/2022] Open
Abstract
Initial glycosylation of mucin-type O-linked protein is catalysed by one of the UDP-GalNAc: polypeptide N-acetyl-galactosaminyl transferase-3 (GalNAc-T3). O-glycosylation is important in the binding of cell adhesion molecules, cell differentiation, invasion, and metastasis in tumours. This study was designed to detect GalNAc-T3 expression in lung adenocarcinoma by using immunohistochemical staining, and to evaluate the relationship between the GalNAc-T3 expression level and prognosis and recurrence in completely resected lung adenocarcinoma patients. A low expression of GalNAc-T3 was detected in the cytoplasm of tumour cells in 79 of 148 patients (53.4%) with lung adenocarcinoma. The low expression of GalNAc-T3 was associated with poorly differentiated tumour (P<0.0001), poor pathologic stage (P<0.0001), lymph node metastasis (P<0.0001), and tumour recurrence (P=0.016). The lung carcinoma patients with low GalNAc-T3 expression had a poorer prognosis than those with high GalNAc-T3 expression, using both univariate and multivariate analyses (overall survival: P<0.0001 and P=0.011, respectively). In addition, multivariate analysis of the clinicopathological characteristics of stage I lung adenocarcinoma indicated that the low expression of GalNAc-T3 was a significant independent factor for predicting poor prognosis and early recurrence (P=0.006, rr=2.87 and P=0.019, rr=3.05, respectively). The low expression of GalNAc-T3 may be a useful marker for predicting poor prognosis and early recurrence in completely resected lung carcinoma patients, particularly patients with stage I diseases.
Collapse
Affiliation(s)
- C Gu
- Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
| | - T Oyama
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - T Osaki
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - J Li
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - M Takenoyama
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - H Izumi
- Department of Molecular Biology, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - K Sugio
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - K Kohno
- Department of Molecular Biology, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| | - K Yasumoto
- Department of Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan
| |
Collapse
|
40
|
Osaki T, Oyama T, Takenoyama M, Taga S, So T, Yamashita T, Nakata S, Sugio K, Yasumoto K. [Assessment of prognosis and p 53 mutations in patients with multiple tumors of the lung; intrapulmonary metastasis or double primary cancers?]. Kyobu Geka 2002; 55:25-9. [PMID: 11797404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
To assess whether a satellite lesion in the primary-tumor lobe is intrapulmonary metastasis from primary cancer (pm 1) or they are double primary lung cancers, we examined the postoperative prognosis of patients with pm 1 and the p 53 genetic differentiation between a satellite lesion and a primary lesion. Of 772 consecutive patients with N0-2M0 non-small cell lung cancer who underwent surgical resections between 1979 and 2000, 31 patients had a satellite lesion in the primary-tumor lobe. The 5-year survival rate was 26.3% in the pm 1 (+) T 4 group (n = 37), 14.7% in the pm 1 (-) T 4 group (n = 43), and 32.5% in the T 3 group (n = 132), suggesting that pm 1 cases should be classified as T 3. We examined 16 of 37 patients with pm 1 for mutations of the p 53 gene occurring exons 5 through 8 by the fluorescence-based polymerase chain reaction single-strand conformation polymorphism. Seven of the 16 patients analyzed had at least one p 53 mutations in their tumors. The mutational status of the p 53 gene was discordant in 5 patients, suggesting they were double primary lung cancers. The mutational status including DNA sequencing of the p 53 gene was concordant in 2 patients, suggesting they were intrapulmonary metastases. It remains arguable in the TNM staging system whether a satellite lesion in the primary-tumor lobe is intrapulmonary metastasis from primary cancer or they are double primary lung cancers.
Collapse
Affiliation(s)
- T Osaki
- Department of Surgery II, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001; 1:61-7. [PMID: 12467239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
Aberrant methylation of CpG islands in promoter regions of tumor cells is one of the major mechanisms for silencing of tumor suppressor genes. We determined the frequency of aberrant promoter methylation of the p16, adenomatous polyposis coli (APC), H-cadherin (CDH13), glutathione S-transferase P1 (GSTP1), O6-methylguanine-DNA-methyltransferase (MGMT), retinoic acid receptor beta-2 (RAR beta), E-cadherin (CDH1), and RAS association domain family 1A (RASSF1A) genes in 198 tumors consisting of small cell lung cancers [SCLCs (n = 43)], non-small cell lung cancers [NSCLCs (n = 115)], and bronchial carcinoids (n = 40). The profile of methylated genes in the two neuroendocrine tumors (SCLC and carcinoids) were very different from that of NSCLC. However, whereas the overall pattern of aberrant methylation of carcinoids was similar to that of SCLC, carcinoids had lower frequencies of methylation for some of the genes tested. There were also significant differences in the methylation profiles between the two major types of NSCLC, adenocarcinoma and squamous cell carcinoma. We performed cluster analysis and found that SCLCs clustered with other SCLCs and carcinoids but not with NSCLCs, whereas the NSCLCs tended to cluster together. Within NSCLCs, adenocarcinomas and squamous cell carcinomas clustered with their respective histological types. Finally, we compared the methylation profiles of SCLC and NSCLC tumors and their respective cell lines (n = 44). In general, methylation frequencies were higher in tumor cell lines, but these differences were seldom significant. Thus, tumor cell lines appear to be suitable models to study aberrant DNA methylation. We conclude that SCLC, carcinoids, squamous cell carcinomas, and adenocarcinomas of the lung have unique profiles of aberrant methylation. Our findings should help us understand differences in the pathogenetic mechanisms of lung cancers.
Collapse
Affiliation(s)
- S Toyooka
- Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8563, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K, Sugimachi K. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer 2001; 34:233-41. [PMID: 11679182 DOI: 10.1016/s0169-5002(01)00246-x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
OBJECTIVES We attempted to determine if the degree of angiogenesis can serve as a prognostic factor in the case of completely resected non-small cell lung cancer patients, with special reference to the center and the periphery of the tumor tissue. METHOD For 255 Japanese patients who underwent completely resected non-small cell lung cancer (NSCLC), micro vessel density (MVD) was assessed by visual quantification of microvessels immunostained with anti-CD34 monoclonal antibody in 5 m section. Vascular endothelial growth factor (VEGF) was also immunostained on the same paraffin block specimen. RESULTS MVD at the center (MVD-c) and that at the periphery (MVD-p) were frequently different in each individual although a weak positive correlation was observed (r=0.499, P<0.0001). One hundred and one patients with high MVD-p, but not the 107 patients with high MVD-c, showed a significantly higher proportion of advanced stage, larger tumor size and nodal metastasis as compared with MVD. The 5 year survival rate and median survival time for the high MVD-p group were significantly lower than that of low the MVD-p group (43.0%/31 months vs 48.6%/54 months, P=0.0256). As to the relationship among vascular endothelial growth factor (VEGF) and MVD, expression of VEGF was not associated with the degree of MVD. However, patients with high grade MVD-p showed an unfavorable prognosis in cases of high expression of VEGF. CONCLUSION High MVD-p is associated with advancement of NSCLC, and it was particularly apparent in conjunction with high VEGF expression.
Collapse
Affiliation(s)
- C Ushijima
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | | | | | | | | | | |
Collapse
|
43
|
Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001; 7:3151-5. [PMID: 11595709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Transcription factor Y-box binding protein 1 (YB-1) that binds to the inverted CCAAT box is involved not only in transcription of various genes but also in cell proliferation and DNA repair. We determined whether localization of YB-1 in either the nucleus or cytoplasm could serve as a prognostic marker for patients with non-small cell lung cancer (NSCLC). In 196 NSCLC patients, expression of YB-1 protein in the nucleus or cytoplasm was immunohistochemically evaluated. Of the 196 tumors examined, 88 (44.9%) were positive for YB-1 expression in the nucleus. Nuclear YB-1 expression significantly correlated with T factor, lymph node metastasis, and stage of the disease. Patients with a nuclear YB-1 tumor had a poorer prognosis than did those with a cytoplasmic YB-1 tumor in all of the NSCLC patients (P = 0.0494) and in patients with squamous cell carcinoma (P = 0.0313) but not in patients with adenocarcinomas. Nuclear localization of the YB-1 protein may prove to be an important factor of disease progression for patients with NSCLC, in particular, in cases of squamous cell carcinoma.
Collapse
Affiliation(s)
- K Shibahara
- Departments of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Tsukamoto S, Sugio K, Sakada T, Ushijima C, Yamazaki K, Sugimachi K. Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001; 34:83-90. [PMID: 11557117 DOI: 10.1016/s0169-5002(01)00216-1] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The cell cycle progression is governed by a family of cyclin-dependent kinases, which are regulated by associated cyclins and by phosphorylation. p27, a cyclin-dependent kinase inhibitor, regulates the progression from G1 into the S phase by binding and inhibiting cyclin/cdks. Although p27 mutations in human tumors are extremely rare, a reduced expression of p27 might to lead to a progression of cancer cells. METHODS We examined tissues that had been surgically excised from 161 unselected Japanese patients with non-small cell lung cancer, and investigated the p27 protein expression by immunohistochemistry. RESULTS A reduced expression of the p27 protein was found in 63 cases (39.0%). Statistical correlation was found between the reduced p27 expression and advanced stage, although no correlation was found between the level of p27 expression and the gender, T factor, N factor or histological differentiation. The 5-year survival rate in the reduced group was 35.4%, which was statistically poorer than the 63.2% rate in the normal group (P=0.0016), in patients with complete resection. In a multivariate analysis, the level of p27 expression was found to be an independent prognostic indicator. CONCLUSIONS We demonstrated the expression of p27 protein to be a biological prognostic indicator which can indicate the subsets of patients with either a good or poor prognosis, in patients who underwent surgical resection.
Collapse
Affiliation(s)
- S Tsukamoto
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
| | | | | | | | | | | |
Collapse
|
45
|
Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer 2001; 95:232-9. [PMID: 11400116 DOI: 10.1002/1097-0215(20010720)95:4<232::aid-ijc1040>3.0.co;2-5] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Although the tumor suppressor p53 protein (P53) immunoreactivity and its gene (p53) mutation were reported to be significant prognostic indicators for human lung adenocarcinomas, little is known regarding the relationship between the heterogeneous distribution of P53 and its genetic status in each tumor focus and the clinicopathological significance. To determine how P53 is heterogeneously stabilized in patients, we compared P53 expression to both the p53 allelic mutation in exon 2 approximately 9 by polymerase chain reaction-single strand conformation polymorphism using microdissected DNA fractions, and the immunohistochemical MDM2 expression. Of the 48 positive to P53 in 118 lung adenocarcinomas examined, 10 with heterogeneous P53 expression were closely examined. The higher P53 expression foci in 7 of 10 cases were less differentiated, histologically in respective cases, and were frequently associated with fibrous stroma. Two had genetic mutations in exon 7 of the p53 gene in both the high and low P53 expression foci of cancer tissue indicating no apparent correlation between heterogeneous P53 expression and the occurrence of gene mutation. Immunohistochemical expression of MDM2 was significantly lower in high P53 expression areas (p < 0.05, the mean labeling indices of high and low P53 expression areas being 4.2 +/- 5.4% and 13.6 +/- 12.2%, respectively). In addition, among all the 118 cases examined, MDM2 expression was significantly suppressed in cases of p53 gene mutation, simultaneously with P53 overexpression, as compared with cases without both the p53 mutation and expression (p < 0.001). These findings suggest that the heterogeneous stabilization of P53 in human lung adenocarcinomas could be partly due to suppressed MDM2 expression. The overexpression of non-mutated P53 may afford a protective mechanism in human lung adenocarcinomas.
Collapse
Affiliation(s)
- T Koga
- Department of Pathophysiological and Experimental Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001; 8:737-43. [PMID: 11410775 DOI: 10.3892/or.8.4.737] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
p21waf1 is a downstream effector of p53, and mediates growth arrest by inhibiting the action of G1 cyclin-dependent kinases. Cyclin D1 is a cell-cycle regulator essential for G1 phases progression and a candidate proto-oncogene implicated in the pathogenesis of several human tumor types. Cyclin D1 overexpression and the absence of retinoblastoma (Rb) protein have been frequently seen in various types of cancer, including lung cancer. The aim of this study was to clarify the relationship between the expressions of p21waf1, cyclin D1, and Rb protein, and to investigate the correlation between these protein expressions and the clinical features of the patients, and their prognoses. We immunohistochemically examined 92 samples of resected non-small cell lung cancer for p21waf1, cyclin D1, and Rb expression. Of the 92 specimens examined, 43 cases (46.7%) showed p21waf1 expression, 23 cases (25.0%) showed cyclin D1 overexpression, and 61 cases (66.3%) showed Rb expression. No correlation was observed between the expressions of p21waf1, cyclin D1, and Rb. There was no association of p21waf1 and cyclin D1 immunoreactivity with gender, disease stage, or histological types of the tumor. Regarding the prognosis in 79 cases with complete resection, no statistical differences were observed according to the degree of expression of these three factors. However, when unfavorable prognostic factors were considered to be the positive expression of p21waf1, positive of cyclin D1, and negative of Rb, the 5-year disease-free survival rate in the group with 2 or 3 unfavorable prognostic factors was 21.1%, which was statistically poorer than the 45.4% in the group with 0 or 1 unfavorable prognostic factor (p=0.0138). We conclude that examination of the expression of cell cycle regulators, such as p21waf1, cyclin D1, and Rb, is useful as a prognostic indicator, when these proteins' expression is analyzed in combination.
Collapse
Affiliation(s)
- G Saitoh
- Department of Surgery and Science,Graduate School of medical Sciences, Kyushu Universioty, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.
| | | | | | | |
Collapse
|
47
|
Koga T, Hashimoto S, Sugio K, Yoshino I, Mojtahedzadeh S, Matsuo Y, Yonemitsu Y, Sugimachi K, Sueishi K. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res 2001; 7:1730-8. [PMID: 11410513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Although human lung adenocarcinoma has diverse histological subtypes, the correlation between histological subtypes and occurrence of the p53 gene mutation has been given less attention. We investigated 145 surgically resected lung adenocarcinomas to search for the incidence of p53 mutations and for record data on survival in each histological subtype, according to the new WHO criteria (1999). The frequency of p53 mutation in bronchioloalveolar carcinoma (BAC; 0% in 17 cases) and BAC with invasive growth component (BAC-invasive; 11% in 27 cases), which is conventionally categorized as the mixed subtype in WHO typing, were apparently significantly lower than in other types (non-BAC including acinar, papillary, solid, or mixed histology with these subtypes; 48% in 101 cases; P < 0.01). Multivariate analysis revealed that the histological subtype including BAC-invasive was a strong, independent, and significant prognostic factor (P < 0.03), as were tumor size and pathological stage (P < 0.001 and 0.002, respectively) for overall survival. However, the occurrence of p53 mutation itself was seen to be significant only in case of the univariate analysis. Therefore, histological subtyping may be a better prognostic indicator than is p53 mutation. These findings suggest that the WHO classification with the BAC and BAC-invasive from other histological subtypes may prove useful to predict the outcome for surgically treated patients with lung adenocarcinoma.
Collapse
Affiliation(s)
- T Koga
- Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Hamatake M, Ishida T, Yamazaki K, Baba H, Maehara Y, Sugio K, Sugimachi K. Lung cancer with p53 expression and a solitary metastasis to the stomach: a case report. Ann Thorac Cardiovasc Surg 2001; 7:162-5. [PMID: 11481023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
Lung cancer with a solitary metastasis to the stomach occurred in a 65-year-old man, surgically treated for gastric metastasis was followed by pulmonary resection. The gastric metastasis accompanied by upper gastrointestinal hemorrhage. After total gastrectomy to control this hemorrhage, a left lower lobectomy with a partial resection of the lingular segment and combined resection of the chest wall were done. Histopathological features of both the primary tumor in the left lower lobe and the gastric tumor were poorly differentiated adenocarcinoma, and showed the same immunoreactivities of p53 protein, carcinoembryonic antigen and keratin. These results indicate that the gastric tumor was a metastasis originated from the lung cancer.
Collapse
Affiliation(s)
- M Hamatake
- Department of Surgery II, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | | | | | | | | | | | | |
Collapse
|
49
|
Sugio K, Tsukamoto S, Ushijima C, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yano T, Sugimachi K. Clinical significance of the Rb expression in adenocarcinoma of the lung. Anticancer Res 2001; 21:1931-5. [PMID: 11497280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
BACKGROUND Altered retinoblastoma gene expression has been found in various types of cancers including non-small cell lung cancer (NSCLC) and some reports have shown it also to be associated with a poor clinical prognosis in NSCLC. MATERIALS AND METHODS We evaluated the expression of Rb protein by immunohistochemistry in 90 patients with lung adenocarcinoma who underwent surgical resection and determined its prognostic significance. Also, the expression of p27 by immunohistochemistry and the mutations of the p53 gene by PCR-SSCP were evaluated. RESULTS Fifty-one out of 90 tumors (56.7%) had reduced expression of the Rb gene. There were no statistical differences between the Rb expression level and clinicopathological status. There was no correlation between the Rb expression level and the p53 mutations or the p27 expression level. The 5-year survival rate in the normal group was 55.1%, which was poorer than that of 73.0% in the reduced group, but showed no statistical difference (p=0.0981). In patients with a reduced Rb-expression, the survival rate of the p53 mutation group tended to show a poorer prognosis than that of the p53 normal group (p=0.0880). In addition, the survival rate of the negative p27 expression group tended to show a poorer prognosis than that of the positive p27 expression group (p=0.0537). CONCLUSIONS The Rb expression status was not significant as an individual factor for evaluating the prognosis in adenocarcinoma of the lung. Analyses of the accumulation of genetic alteration are necessary to identify the subset of patients with a poor prognosis.
Collapse
Affiliation(s)
- K Sugio
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Sugimachi K. Direct IFNluence of interferon-gamma on proliferation and cell-surface antigen expression of non-small cell lung cancer cells. Lung Cancer 2000; 30:169-74. [PMID: 11137201 DOI: 10.1016/s0169-5002(00)00136-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In order to clarify the anti-tumor activity of IFN-gamma, we investigated the direct IFNluence of IFN-gamma on both the growth and cell-surface antigen expression of tumor cells. In the present study, four human lung cancer cell lines were used; two squamous cell lines (QG-56, QG-95) and two adenocarcinoma cell lines (PC-9, PC-12). In all four tumor cell lines, mutations were detected in exon 7 of the p53 gene by a PCR-FSSCP analysis. The proliferation of QG-56 or QG-95 was inhibited by IFN-gamma in a dose-dependent manner with about 70% inhibition at 1000 JRU/ml while that of PC-9 was slightly inhibited with maximally 25% inhibition at 1000 JRU/ml. The growth of PC-12 was not inhibited at all. In QG-56, QG-95 and PC-9, the fraction of cells in G1 phase increased while the fractions of cells in both S and G2/M phases decreased after exposure to IFN-gamma (200 JRU/ml) for 72 h. The growth inhibition by long-term exposure to IFN-gamma was irreversible in QG-56. After culture in the presence of IFN-gamma (200 JRU/ml) for 14-16 days, tumor cells were examined for expression of various antigens, including HLA-class I, HLA-class II, and CEA. In all cell lines but PC-12, 100% of cells expressed HLA-class I after incubation with IFN-gamma. Both HLA-class II and CEA were also induced in those cell lines. The proportion of HLA-class II-positive cells or that of CEA-positive cells varied among the cell lines. Of the three antigens, the degree of HLA-class II expression paralleled that of growth inhibition by IFN-gamma treatment. These results suggested that in various function of IFN-gamma against tumor cells, the anti-proliferative effect might be closely linked with the induction of HLA-class II probably through a similar posttranscriptional process, independent of the function of p53 gene.
Collapse
Affiliation(s)
- T Yano
- Department of Thoracic Surgery, National Kyushu Medical Center, Fukuoka, Japan
| | | | | | | | | | | | | |
Collapse
|